News
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210